Business models and opportunities for cancer vaccine developers

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 10, 2012, Pages 1431-1438

  Kudrin, Alex ^a  

^a Pharmaceutical Medicine   (United Kingdom)

Author keywords

Business model; Cancer vaccines; Emerging markets; Federated model; Oncology market

Indexed keywords

EID: 84868266974     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.20629     Document Type: Note

References (27)

1. Insights B. The cancer market outlook to 2016, 2011; 1-55. www.business-insights.com.
2. Dendreon Corporation PharmaVitae Emerging Biopharma Company Analysis. Datamonitor 2012; 1-86. www.datamonitor.com.
3. Market and Product Forecasts. Targeted. Cancer Ther. Datamonitor. 2011; 5-76; www.datamonitor. com.
4. Datamonitor. Pipeline Insight: Thereputic Cancer Vaccines, 2009; 1-12. www.datamonitor.com.
5. Rodríguez PC, Rodríguez G, González G, Lage A. Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy. MEDICC Rev 2010; 12:17-23; PMID:20387330.
6. Cancer therapy China. Gene Therapy (Gendicine). 2009; Available from: http://www.cancertherapychina. com/index.php?option=com-content&view=arti cle&id=84&Itemid=23 Accessed on April 10, 2012.
7. Datamonitor. Stakeholder opinions: Bladder cancer. New drugs needed to replace ineffective 20-year old drugs. 2008; 5-76. www.datamonitor.com.
8. Sievert KD, Amend B, Nagele U, Schilling D, Bedke J, Horstmann M, et al. Economic aspects of bladder cancer: what are the benefits and costs? World J Urol 2009; 27:295-300; PMID:19271220; http://dx.doi. org/10.1007/s00345-009- 0395-z.
9. Gordon EM, Hall FL. Noteworthy clinical case studies in cancer gene therapy: tumor-targeted Rexin-G advances as an efficacious anti-cancer agent. Int J Oncol 2010; 36:1341-53; PMID:20428757; http:// dx.doi.org/10.3892/ijo- 00000619.
10. Epeius Biotechnologies. Rexin-G Epeius Biotechnologies. 2009; Available from: http://www. epeiusbiotech.com/oncology-RexinG.asp Accessed on April 6, 2012.
11. Shirvill J. Innovations and Opportunities in Therapeutic Vaccines. Business Insights. 2010; 5-68.
12. Pammolli F, Magazzini L, Riccaboni M. The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discov 2011; 10:428-38; PMID:21629293; http:// dx.doi.org/10.1038/nrd3405.
13. Adams CP, Brantner VV. Estimating the cost of new drug development: is it really 802 million dollars? Health Aff (Millwood) 2006; 25:420-8; PMID:16522582; http://dx.doi.org/10.1377/ hlthaff.25.2.420.
14. Adams CP, Brantner VV. Spending on new drug development1. Health Econ 2010; 19:130-41.; PMID:19247981; http://dx.doi.org/10.1002/ hec.1454
15. DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther 2010; 87:272-7; PMID:20130567; http:// dx.doi.org/10.1038/clpt. 2009.295.
16. PricewaterhouseCoopers Health Research Institute. Pharma 2020: Virtual R&D. Available from: www. pwc.com/pharma2020. 2008; Accessed on April 11, 2012.
17. Schmid EF, Smith DA. Is pharmaceutical R&D just a game of chance or can strategy make a difference? Drug Discov Today 2004; 9:18-26; PMID:14761802; http://dx.doi.org/10.1016/S1359- 6446(04)02951-4.
18. McKinsey & Company. Invention reinvented. McKinsey perspective on pharmaceutical R&D. 2010; Available from www.mckinsey.com Accessed on April 13, 2012.
19. PricewaterhouseCoopers Health Research Institute. Pharma 2020: Challenging business models. 2009; Available from: www.pwc.com/pharma2020. Accessed on April 11, 2012.
20. Datamonitor. Stakeholder Opinions: Gene Therapy. Gene therapy to deliver after 20 years of clinical development. 2009; 10-68. www.datamonitor.com
21. Müller S, Weigelt J. Open-access public-private partnerships to enable drug discovery-new approaches. IDrugs 2010; 13:175-80; PMID:20191434.
22. Faigen N. Pervasis acquisition puts Shire in regenerative medicine sweet spot. 2012; Available from: http://www.scripintelligence.com/home/ Pervasisacquisition- puts-Shire-in-regenerative-medicinesweet- spot-329259 Accessed on April 13, 2012.
23. Ernst & Young. Beyond borders: Global biotechnology report. 2011; 4-74. www.ey.com/ Publication/vwLUAssets/Global-Biotechnology- Report-2011/$FILE/Biotech-BeyondBorders-2011. pdf 24. Datamonitor. Oncology Market Access in China Market bolstered by rising incidence and improved regulatory environment. 2011; 2-61. www.datamonitor. com 25. PharmaLive. Oncology Market Soars in China. 2011; Available from: http://pharmalive.com/magazines/ medad/view. cfm?articleID=9544 Accessed April 13, 2012.
24. Landsdell M. Innovative drug discovery in emerging markets. Business Insights. 2010; 4-51.
25. Chung S. Technology Innovation and Economic Growth Korean Experiences. World Bank Workshop, 2005; 3-22.
26. World Bank. Korea as a Knowledge Economy: Evolutionary Process and Lessons Learned. The World Bank, Washington D.C. 2006; 2-15.
27. KFDA. Recent trends and Korea's cases in the development of gene therapy products KFDA. 2008; Available from: http://www.bioin.or.kr/upload.do?c md=download&seq=7676&bid=industry. Accessed on April 5, 2012.